Barrington Research analyst Gary Prestopino maintains Dorman Products (NASDAQ:DORM) with a Outperform and raises the price target from $104 to $130.
Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $48
Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $55 to $48.